PharmaEngine's Pancreatic Cancer Drug Seeks Approval in Europe
May 04, 2015 at 11:41 AM EDT
PharmaEngine of Taiwan announced that its licensing partner, Merrimack Pharma of Boston, and its sublicensing partner, Baxter International, have applied for European marketing approval of MM-398, a liposome-encased form of irinotecan. The drug is indicated to treat metastatic pancreatic cancer in patients previously treated with gemcitabine. PharmaEngine retains rights to the drug in Taiwan, but out-licensed the global rights (ex-Taiwan) to Merrimack in 2011 for $10 million upfront and $210 million in milestones, plus royalties. More details.... Stock Symbols: (TWO:4162) (NSDQ: MACK) (NYSE: BAX) Share this with colleagues: // //